Patents by Inventor Jiemiao HU

Jiemiao HU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
    Publication number: 20220380429
    Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
    Type: Application
    Filed: July 21, 2022
    Publication date: December 1, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Shulin LI, Jiemiao HU, Xueqing XIA
  • Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
    Patent number: 11512141
    Abstract: Provided herein are anti-FGL2 monoclonal antibodies. Further provided herein are methods to reverse suppressive immune mechanisms, such as for the treatment of cancer or infectious diseases.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: November 29, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Shulin Li, Jun Yan, Jiemiao Hu, Xueqing Xia, Qingnan Zhao
  • T cells expressing membrane-anchored IL-12 for the treatment of cancer
    Patent number: 11421010
    Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 23, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Shulin Li, Jiemiao Hu, Xueqing Xia
  • MODIFIED IL-12 T CELL THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220118015
    Abstract: Provided herein are chimeric antigen receptor (CAR)-like constructs comprising tumor-targeted and membrane-anchored IL-12. Also provided herein are T cells expressing the CAR-like IL-12 construct. Further, methods of treating cancer comprising administering T cells expressing CAR-like IL-12 are provided herein.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 21, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shulin LI, Jiemiao HU, Xueqing XIA, Qingnan ZHO
  • FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF
    Publication number: 20210393753
    Abstract: Provided herein is an FGL2 neutralization cell therapy comprising immune cells expressing a FGL2 neutralization construct. Further provided are methods for the treatment of cancer comprising administering the FGL2 neutralization cell therapy.
    Type: Application
    Filed: November 6, 2019
    Publication date: December 23, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Shulin LI, Jiemiao HU, Xueqing XIA
  • FGL2 MONOCLONAL ANTIBODIES AND THEIR USE IN TREATING MALIGNANT TUMORS
    Publication number: 20200055955
    Abstract: Provided herein are anti-FGL2 monoclonal antibodies. Further provided herein are methods to reverse suppressive immune mechanisms, such as for the treatment of cancer or infectious diseases.
    Type: Application
    Filed: May 7, 2018
    Publication date: February 20, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Shulin LI, Jun YAN, Jiemiao HU, Xueqing XIA, Qingnan ZHAO
  • T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
    Publication number: 20200048322
    Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 13, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Shulin LI, Jiemiao HU, Xueqing XIA